Molecular chemotherapy for breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Gene therapy for breast cancer faces challenges in targeted delivery, particularly for systemic approaches.
• Preclinical models have explored antibody and growth factor receptor ligand methods for targeting.

Purpose of the Study:

• This review focuses on advancing breast cancer gene therapy through tissue-specific promoters.
• It examines promoters differentially upregulated in breast cancer and those responsive to physiological stimuli.

Main Methods:

• Investigates tissue-specific promoters (Muc-1, CEA, PSA, HER-2, Myc, L-plastin, secretory leukoproteinase inhibitor).
• Explores inducible elements like glucose-regulated, hypoxia-response, and radiation-inducible promoters (EGR-1, p21, tissue type plasminogen activator).
• Discusses prodrug activation systems (5-fluorocytosine, analogues) and freely diffusible agents (cyclophosphamide, ifosfamide, thymidine phosphorylase).

Main Results:

• Tissue-specific promoters show differential upregulation in breast cancer.
• Inducible elements offer additional specificity for cancer targeting.
• Alkylating agents demonstrate advantages over antimetabolites, including cytotoxicity to both cycling and non-cycling cells and enhanced diffusion without gap junctions.

Conclusions:

• Tissue-specific and inducible promoters are crucial for next-generation breast cancer gene therapy.
• Alkylating agents represent a more effective therapeutic strategy compared to antimetabolites for gene-directed enzyme prodrug therapy.
• The bystander effect and the use of human enzymes in prodrug systems are important considerations for efficacy and immune response modulation.